The global CAR-T cell therapy market was valued at USD 7.31 billion in 2024, and it is projected to grow to USD 188.84 billion by 2034, exhibiting a robust compound annual growth rate (CAGR) of 36.8% during the period of 2025–2034. This dramatic growth is fueled by breakthroughs in immune-oncology , advancements in T-cell engineering , and an expanding clinical pipeline that promises to revolutionize cancer treatment. Market Overview Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as one of the most promising and cutting-edge treatments in the field of immunotherapy. CAR-T cell therapy involves modifying a patient’s T cells to express receptors specific to cancer cells, enabling the immune system to more effectively recognize and attack the tumor. This personalized form of cellular therapy has already demonstrated transformative success in treating various hematologic cancers, including leukemia and lymphoma, and is now expanding into solid tumor indicat...